JARDIANCE Market

“JARDIANCE Market Size, Forecast, and Market Insight − 2032” report provides comprehensive insights about JARDIANCE for Diabetic Kidney Disease (DKD) in the seven major markets. A detailed picture of the JARDIANCE for DKD in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the JARDIANCE for DKD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JARDIANCE market forecast analysis for DKD in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in DKD.

Drug Summary

JARDIANCE (empagliflozin) is an oral, once-daily, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor. Inhibition of SGLT2 with empagliflozin in people with type 2 diabetes and high blood sugar levels prevents sugar from being re-absorbed by the kidneys, leading to the excretion of excess sugar in the urine. In addition, the initiation of empagliflozin also prevents salt from being re-absorbed, leading to increased excretion of salt from the body and reducing the fluid load of the body’s blood vessel system (i.e., intravascular volume). JARDIANCE was the first medicine approved by regulatory authorities to significantly reduce the risk of cardiovascular death or include data on the reduction of the risk of cardiovascular death in the label for adults with type 2 diabetes and established cardiovascular disease.

Dosage and administration 

The recommended dosage for adults is 10 mg orally once daily in the morning.

Mechanism of action

Empagliflozin is an inhibitor of SGLT2, the predominant transporter responsible for the re-absorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, empagliflozin reduces renal re-absorption of filtered glucose and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion. Empagliflozin also reduces sodium re-absorption and increases the delivery of sodium to the distal tubule.

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the JARDIANCE description, mechanism of action, dosage and administration, research and development activities in Diabetic Kidney Disease (DKD).
• Elaborated details on JARDIANCE regulatory milestones and other development activities have been provided in this report.
• The report also highlights the JARDIANCE research and development activities in DKD across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around JARDIANCE.
• The report contains forecasted sales of JARDIANCE for DKD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for DKD.
• The report also features the SWOT analysis with analyst views for JARDIANCE in DKD.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

JARDIANCE Analytical Perspective by DelveInsight

• In-depth JARDIANCE Market Assessment

This report provides a detailed market assessment of JARDIANCE for Diabetic Kidney Disease (DKD) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• JARDIANCE Clinical Assessment

The report provides the clinical trials information of JARDIANCE for Diabetic Kidney Disease (DKD) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights  

• In the coming years, the market scenario for Diabetic Kidney Disease (DKD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JARDIANCE dominance.
• Other emerging products for DKD are expected to give tough market competition to JARDIANCE and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JARDIANCE in DKD.
• Our in-depth analysis of the forecasted sales data of JARDIANCE from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the JARDIANCE in DKD. 

Key Questions

• What is the product type, route of administration and mechanism of action of JARDIANCE?
• What is the clinical trial status of the study related to JARDIANCE in Diabetic Kidney Disease (DKD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JARDIANCE development?
• What are the key designations that have been granted to JARDIANCE for DKD?
• What is the forecasted market scenario of JARDIANCE for DKD?
• What are the forecasted sales of JARDIANCE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?  
• What are the other emerging products available and how are these giving competition to JARDIANCE for DKD?
• Which are the late-stage emerging therapies under development for the treatment of DKD?